Nov 30, 2022 / 04:30PM GMT
Guyn Kim - Piper Sandler & Co., Research Division - Senior Research Analyst
All right. Good morning. Thank you, everyone, for joining us for our next company presentation. My name is Do Kim. I am one of the senior biotech analysts here at Piper. And we have with us Gilead. And it's my pleasure to welcome CMO, Merdad Parsey. Merdad, thank you for being here.
Merdad V. Parsey - Gilead Sciences, Inc. - Chief Medical Officer
My pleasure. Thanks for having me.
Questions and Answers:
Guyn Kim - Piper Sandler & Co., Research Division - Senior Research AnalystSo Gilead has always had a tremendous R&D effort in maintaining its leadership in HIV and viral diseases. But you're always pursuing expansion in other therapeutic areas like oncology and inflammatory diseases. Just so starting out with your oncology efforts. Normally, Trodelvy would be the initial topic, but you put out a press release on your TIGIT interim fourth look, ARC-7 and were expected detailed data in -- toward the second half of December.
Trustpilot
